Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2026)
Aurinia Pharmaceuticals (AUPH) reported EBITDA Margin of 43.85% for Q1 2026, up 676.0% on a YoY basis from 5.65% in Q1 2025, and down 83.97% quarter-over-quarter from 273.55% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals has reported EBITDA Margin for 8 years, with the latest figure at 43.85% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 676.0% year-over-year to 43.85%; the trailing twelve-month figure through Mar 2026 stood at 99.95% (up 8383.0% YoY), and the FY2025 full-year result was 101.48%, up 9900.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 43.85%, down from 273.55% in the prior quarter.
- The five-year high for EBITDA Margin was 273.55% in Q4 2025, with the low at 177.55% in Q1 2022.
- Historically, EBITDA Margin has averaged 9.74% across 5 years, with a median of 15.53% in 2022.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 533372 bps — and 2023, when it tumbled 900 bps.
- Aurinia Pharmaceuticals' EBITDA Margin stood at 89.96% in 2022, then soared by 34 bps to 59.12% in 2023, then jumped by 103 bps to 1.95% in 2024, then soared by 13933 bps to 273.55% in 2025, then sank by 84 bps to 43.85% in 2026.
- The last three EBITDA Margin figures came in at 43.85% (Q1 2026), 273.55% (Q4 2025), and 43.16% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.18 Bn | 1.80 Bn | 71.20 Mn | 43.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.85% |
| Dec 31, 2025 | 273.55% |
| Sep 30, 2025 | 43.16% |
| Jun 30, 2025 | 30.62% |
| Mar 31, 2025 | 37.09% |
| Dec 31, 2024 | 1.95% |
| Sep 30, 2024 | 21.87% |
| Jun 30, 2024 | 1.25% |
| Mar 31, 2024 | -21.62% |
| Dec 31, 2023 | -59.12% |
| Sep 30, 2023 | -24.53% |
| Jun 30, 2023 | -27.77% |
| Mar 31, 2023 | -75.95% |
| Dec 31, 2022 | -89.96% |
| Sep 30, 2022 | -15.53% |
| Jun 30, 2022 | -126.81% |
| Mar 31, 2022 | -177.55% |
| Dec 31, 2021 | -142.63% |
| Sep 30, 2021 | -342.65% |
| Jun 30, 2021 | -710.02% |